Table 2 The clinicopathologic characteristics of nEGFR and cMet expression in NPC patients
Variables | Cases | nEGFR (n, %) | cMET (n, %) | ||||
|---|---|---|---|---|---|---|---|
Low | High | P | Low | High | P | ||
Gender | |||||||
 Male | 94 | 46 (48.9) | 48 (51.1) | 0.405 | 40 (42.6) | 54 (57.4) | 0.868 |
 Female | 74 | 41 (55.4) | 33 (44.6) |  | 32 (43.8) | 41 (56.2) |  |
Age (years) | |||||||
 < 54 | 87 | 41 (47.1) | 46 (52.9) | 0.210 | 35 (40.7) | 51 (59.3) | 0.516 |
 ≥ 54 | 81 | 45 (56.8) | 35 (43.2) |  | 37 (45.7) | 44 (54.3) |  |
T classification | |||||||
 T3 | 24 | 13 (54.2) | 11 (45.8) | 0.801 | 14 (58.3) | 10 (41.7) | 0.104 |
 T4 | 144 | 74 (51.4) | 70 (48.6) |  | 58 (40.6) | 85 (59.4) |  |
N classification | |||||||
 N0 | 87 | 41 (47.1) | 46 (52.9) | 0.210 | 36 (41.9) | 50 (58.1) | 0.736 |
 N1–3 | 81 | 46 (56.8) | 35 (43.2) |  | 36 (44.4) | 45 (55.6) |  |
M classification | |||||||
 M0 | 122 | 63 (51.6) | 59 (48.4) | 0.951 | 54 (44.3) | 68 (55.7) | 0.622 |
 M1 | 46 | 24 (52.2) | 22 (47.8) |  | 18 (40.0) | 27 (60.0) |  |
Clinical stage | |||||||
 III | 49 | 26 (53.1) | 23 (46.9) | 0.832 | 20 (40.8) | 29 (59.2) | 0.699 |
 IV | 119 | 61 (51.3) | 58 (48.7) |  | 52 (44.1) | 66 (55.9) |  |